The number of days alive and out of the hospital within the first 90 days of surgery is greater for robot-assisted surgery, but the clinical significance of the findings unclear.
Study reveals factors that could distinguish PSA bounce from biochemical recurrence after stereotactic body radiation therapy for prostate cancer.
In all studied scenarios, PSA screening appeared more favorable for Black men than for the general population.
Positive surgical margins in patients undergoing robotic partial nephrectomy for renal tumors are associated with adverse oncologic outcomes, a study revealed.
The presence of perineural invasion in a prostate biopsy has important implications for active surveillance.
An interim analysis suggests that axitinib given to patients with complex clear cell renal cell carcinoma tumors significantly reduces tumor size and complexity.
New findings challenge recommendations from the European Association of Urology.
The findings may inform surveillance strategies and improve treatment outcomes.
While socioeconomic disparities are evident, survival differences between racial groups persist after RCC diagnosis.
Some patients with a negative mpMRI while on prostate cancer active surveillance may be able to defer biopsy, according to investigators.
Further studies are needed to evaluate oncologic outcomes after postoperative radiation therapy.
Immune checkpoint inhibitors may be more beneficial than tyrosine kinase inhibitors for patients undergoing cytoreductive nephrectomy for metastatic renal cell carcinoma.
A study examined bladder cancer risk and mortality among nearly 100,000 men from Ontario, Canada, who received 5-alpha reductase inhibitors.
Active surveillance appears to be a safe treatment option for low- and very low-risk prostate cancer, regardless of race, according to investigators.
Approximately one-quarter of patients aged 80 years or older with upper tract urothelial carcinoma are managed expectantly, data show.
Following the approval of cabazitaxel in 2010, there are now an unprecedented number of life-prolonging therapies for men with metastatic disease.
Study characterized patient-reported delays in care of prostate cancer and bladder cancer at the national level.
Grade group 1 prostate cancers declined as a proportion of all prostate cancers.